Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
Oncology Today with Dr Neil Love
00:00
Introduction
Polar X study looked at first-line therapy at diffuse large B cell lymphoma. Patients had to have an IPI score of 2 to 5 in order to enter into the study. Those patients with a log-fold change that was greater than 2.5, their two-year estimated PFS was 87% versus if you did not, your two-year PFS was 66%.
Transcript
Play full episode
